Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Workday Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Workday Inc trades at $188.73 (market cap $44.83B). The key difference: Workday Inc is far larger — about 46.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is more actively traded (4,325,710 versus 2,168,736). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Workday Inc for 38 Days on average.
| MRVI | WDAY | |
|---|---|---|
Market Cap | $972.90M | $44.83B |
Volume | 4,325,710 | 2,168,736 |
Sector | Health | Technology |
52-Week High | $9.00 | $245.67 |
52-Week Low | $2.83 | $112.55 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $1.08B | $45.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Workday (WDAY) trades at $188.77, up 0.28% today, with a bullish technical signal from moving averages and a consensus analyst price target of $203.19. The company has beaten earnings estimates for the last three quarters, with Q3 2026 EPS expected at $2.74. Revenue grew to $8.45 billion in 2025, and recent news highlights AI product launches and strategic partnerships, though layoffs and a fraud investigation present headwinds.
WDAY offers growth potential driven by AI integration and expanding market presence, but faces risks from competitive pressures and execution challenges. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels. Investor sentiment is mixed amid operational adjustments and legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
